ArticleAmerican journal of ophthalmology2023
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine Program: First-Year Outcomes and Implementation Costs.
Article in American journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Glaucoma Among US Adults in 2022.JAMA ophthalmology · 2024Pooled it
- Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine Program: Impact on Vision, Follow-up, and Costs.Ophthalmology · 2025Trial
- Design of a Pragmatic Randomized Controlled Trial for Comparing the Michigan Screening and Intervention for Glaucoma and Eye Health and Telemedicine Protocol with Usual Care for Disease Detection.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Perspectives on eye care access and telemedicine-based glaucoma screening among Latine individuals with limited English proficiency.AJO international · 2025Article
- Time spent on eye disease screening, optical care, and care navigation within a federally qualified health center.AJO international · 2025Article
- Association between self-reported eye conditions in patients at rural federally qualified health centers and vision-targeted health-related quality of life: the AL-SIGHT study.Frontiers in medicine · 2025Article
- Recommendations for the optimization of student led free vision screening programs.BMC medical education · 2024Article
- Eye Care in Federally Qualified Health Centers.Ophthalmology · 2024Article
- Feasibility of Glaucoma Detection Programs for At-Risk Populations Using Existing Health Care Infrastructure.Journal of glaucoma · 2024Article
- Telemedicine Screening for Eye Disorders in Federally Qualified Health Centers: Relationship to Vision-Targeted Health-Related Quality of Life.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2024Article
- Association of Contrast Sensitivity With Eye Disease and Vision-Related Quality of Life.American journal of ophthalmology · 2024Article
- Visual Impairment from Uncorrected Refractive Error among Participants in a Novel Program to Improve Eye Care Access among Low-Income Adults in Michigan.Ophthalmology · 2024Article
- Alabama Screening and Intervention for Glaucoma and Eye Health through Telemedicine (AL-SIGHT): Baseline Results.American journal of ophthalmology · 2024Article
- Identifying, Understanding, and Addressing Disparities in Glaucoma Care in the United States.Translational vision science & technology · 2023Article
- Social Deprivation and the Risk of Screening Positive for Glaucoma in the MI-SIGHT Telemedicine-Based Glaucoma Detection Program.Ophthalmology · 2023Article
- The Impact of Social Vulnerability on Structural and Functional Glaucoma Severity, Worsening, and Variability.Ophthalmology. GlaucomaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThe Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (MI-SIGHT) program aims to engage people who are at high risk of glaucoma; we assess first-year outcomes and costs.
designClinical cohort study.
methodsParticipants ≥18 years of age were recruited from a free clinic and a federally qualified health center in Michigan. Ophthalmic technicians in the clinics collected demographic information, visual function, ocular health history, measured visual acuity, refraction, intraocular pressure, pachymetry, pupils, and took mydriatic fundus photographs and retinal nerve fiber layer optical coherence tomography. Data were interpreted by remote ophthalmologists. During a follow-up visit, technicians shared ophthalmologist recommendations, dispensed low-cost glasses, and collected participant satisfaction. The primary outcome measures were prevalence of eye disease, visual function, program satisfaction, and costs. Observed prevalence was compared with national disease prevalence rates using z tests of proportions.
resultsAmong 1171 participants, the average age was 55 years (SD 14.5 years), 38% were male, 54% identified as Black, 34% as White, 10% as Hispanic, 33% had less than or equal to a high school education, and 70% had an annual income <$30,000. The prevalence of visual impairment was 10.3% (national average 2.2%), glaucoma and suspected glaucoma 24% (national average 9%), macular degeneration 2.0% (national average 1.5%), and diabetic retinopathy 7.3% (national average 3.4%) (P < .0001). Seventy-one percent of participants received low-cost glasses, 41% were referred for ophthalmology follow-up, and 99% were satisfied or very satisfied with the program. Startup costs were $103,185; recurrent costs were $248,103 per clinic.
conclusionsTelemedicine eye disease detection programs in low-income community clinics effectively identify high rates of pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.